Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

Krista L. Lanctôt; Joan Amatniek; Sonia Ancoli-Israel; Steven E. Arnold; Clive Ballard; Jiska Cohen-Mansfield; Zahinoor Ismail; Constantine Lyketsos; David S. Miller; Erik Musiek; Ricardo S. Osorio; Paul B. Rosenberg; Andrew Satlin; David Steffens; Pierre Tariot; Lisa J. Bain; Maria C. Carrillo; James A. Hendrix; Heidi Jurgens; Brendon Boot

doi:10.1016/j.trci.2017.07.001

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

Krista L. Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, Steven E. Arnold, Clive Ballard, Jiska Cohen-Mansfield, Zahinoor Ismail, Constantine Lyketsos, David S. Miller, Erik Musiek, Ricardo S. Osorio, Paul B. Rosenberg, Andrew Satlin, David Steffens, Pierre Tariot, Lisa J. Bain, Maria C. Carrillo, James A. Hendrix, Heidi Jurgens, Brendon Boot

School of Medicine

Research output: Contribution to journal › Review article › peer-review

102 Scopus citations

Abstract

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.

Original language	English (US)
Pages (from-to)	440-449
Number of pages	10
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	3
Issue number	3
DOIs	https://doi.org/10.1016/j.trci.2017.07.001
State	Published - Sep 2017

Keywords

Agitation
Alzheimer's disease
Apathy
Delusions
Depression
Hallucinations
Neuropsychiatric symptoms
Sleep disturbance
Trial design

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1016/j.trci.2017.07.001

Cite this

Lanctôt, K. L., Amatniek, J., Ancoli-Israel, S., Arnold, S. E., Ballard, C., Cohen-Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., Osorio, R. S., Rosenberg, P. B., Satlin, A., Steffens, D., Tariot, P., Bain, L. J., Carrillo, M. C., Hendrix, J. A., Jurgens, H., & Boot, B. (2017). Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 3(3), 440-449. https://doi.org/10.1016/j.trci.2017.07.001

Lanctôt, KL, Amatniek, J, Ancoli-Israel, S, Arnold, SE, Ballard, C, Cohen-Mansfield, J, Ismail, Z, Lyketsos, C, Miller, DS, Musiek, E, Osorio, RS, Rosenberg, PB, Satlin, A, Steffens, D, Tariot, P, Bain, LJ, Carrillo, MC, Hendrix, JA, Jurgens, H & Boot, B 2017, 'Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 3, no. 3, pp. 440-449. https://doi.org/10.1016/j.trci.2017.07.001

@article{c069ffc263bb4bc38a162cb10473aa0f,

title = "Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms",

abstract = "Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.",

keywords = "Agitation, Alzheimer's disease, Apathy, Delusions, Depression, Hallucinations, Neuropsychiatric symptoms, Sleep disturbance, Trial design",

author = "Lanct{\^o}t, {Krista L.} and Joan Amatniek and Sonia Ancoli-Israel and Arnold, {Steven E.} and Clive Ballard and Jiska Cohen-Mansfield and Zahinoor Ismail and Constantine Lyketsos and Miller, {David S.} and Erik Musiek and Osorio, {Ricardo S.} and Rosenberg, {Paul B.} and Andrew Satlin and David Steffens and Pierre Tariot and Bain, {Lisa J.} and Carrillo, {Maria C.} and Hendrix, {James A.} and Heidi Jurgens and Brendon Boot",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2017",

month = sep,

doi = "10.1016/j.trci.2017.07.001",

language = "English (US)",

volume = "3",

pages = "440--449",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Neuropsychiatric signs and symptoms of Alzheimer's disease

T2 - New treatment paradigms

AU - Lanctôt, Krista L.

AU - Amatniek, Joan

AU - Ancoli-Israel, Sonia

AU - Arnold, Steven E.

AU - Ballard, Clive

AU - Cohen-Mansfield, Jiska

AU - Ismail, Zahinoor

AU - Lyketsos, Constantine

AU - Miller, David S.

AU - Musiek, Erik

AU - Osorio, Ricardo S.

AU - Rosenberg, Paul B.

AU - Satlin, Andrew

AU - Steffens, David

AU - Tariot, Pierre

AU - Bain, Lisa J.

AU - Carrillo, Maria C.

AU - Hendrix, James A.

AU - Jurgens, Heidi

AU - Boot, Brendon

PY - 2017/9

Y1 - 2017/9

N2 - Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.

AB - Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.

KW - Agitation

KW - Alzheimer's disease

KW - Apathy

KW - Delusions

KW - Depression

KW - Hallucinations

KW - Neuropsychiatric symptoms

KW - Sleep disturbance

KW - Trial design

UR - http://www.scopus.com/inward/record.url?scp=85027417429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027417429&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2017.07.001

DO - 10.1016/j.trci.2017.07.001

M3 - Review article

C2 - 29067350

AN - SCOPUS:85027417429

SN - 2352-8737

VL - 3

SP - 440

EP - 449

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 3

ER -